News

Legal 500 EMEA 2022: “Partner involvement, all areas in-house, professional juniors”

This week the Legal 500 published its’ 2022 edition. We are honoured to again have received excellent rankings this year. BarentsKrans has been ranked as Top Tier Firm in Employment Law and has been recommended in no less than ten practice areas. A special mention goes to Joost Fanoy who was listed as Leading Individual
Read more ›

Chambers Europe 2022: “accessible, specialist and pragmatic”

After receiving honourable mentions in the Chambers Global Guide 2022 last month, we are proud and grateful to have been ranked in the Chambers Europe Guide 2022. Chambers Europe ranks the leading lawyers and law firms across Europe and is one of the leading guidebooks within the international field of advocacy. The annual rankings are
Read more ›

Telecoms update | Court orders submission of third party license and settlement agreements in FRAND case and imposes confidentiality regime; AASI granted ex parte

Recently, two interesting judgments were published in separate SEP/FRAND proceedings. The first decision pertains to a confidentiality regime and the second to an ex parte AASI. Confidentiality regime In the SEP/FRAND proceedings between Philips et al. vs. Xiaomi et al the District Court of The Hague (“DC”) decided on 14 July 2021 (decision published in
Read more ›

Chambers Global 2022 rankings: excellent results for BarentsKrans

We are excited to share the newest rankings of the Chambers Global Guide 2022. BarentsKrans once again received several honourable mentions for Corporate/ M&A, Dispute Resolution and Intellectual Property. Mentions Chambers Global 2022 The Chambers Global Guide ranks the top lawyers and law firms in over 200 jurisdictions across the world. The annual rankings are based
Read more ›

Pharma update | Court of Appeal overturns ruling District Court in Astrazeneca v Menzis

In an earlier Pharma Update, we reported on the judgment of the District Court of The Hague of 14 October 2020 in which AstraZeneca AB (“AstraZeneca”) was ordered to pay damages to health insurer Menzis Zorgverzekeraar NV (“Menzis”) for having enforced a patent that was later invalidated against a generic company.   This judgment has now
Read more ›